Key facts
- NanoSyrinx’s last known valuation is $27.4M.
- It has raised $20.1M; the latest was Later Stage VC ($12.5M) in Aug 2024.
- Notable investors include Innovate UK, Octopus Ventures, BGF (Financial Services), Future Planet Capital, UK Innovation & Science Seed Fund — 14 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 14 names
- ·Watchlist + deal alerts for NanoSyrinx
- ·The full record, as it builds
Funding rounds
No funding rounds for NanoSyrinx are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About NanoSyrinx
Developer of a novel biologics drug research platform designed to serve the biopharmaceutical sector. The company leverages a synthetic biology approach to create a completely novel method for targeted drug delivery of therapeutic proteins and peptides to cell interiors and delivers payloads directly to the cytosol of targeted cells, enabling medical practitioners to improve efficacy and treatment outcomes.
- Sector
- Healthcare
- HQ
- Coventry, United Kingdom
- Founded
- 2018
- Employees
- 18
- Website
- nanosyrinx.com/
- Ownership
- Privately Held (backing)
NanoSyrinx doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in NanoSyrinx shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on NanoSyrinx in its N-PORT filings yet. We sweep new filings monthly.